Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Patupilone in Advanced Hepatocellular Carcinoma
NCT00273312Phase 2Completed
- Sponsor
- Novartis
- Start
- Jan 2006
- Primary completion
- Oct 2006
- Modality
- Covalent Small Molecules, RNA-Targeting Small Molecules, Classical Binding Small Molecules
- Countries
- 4
01
Overview
Phase 2, open-label, single-arm trial of patupilone in hepatocellular carcinoma (HCC), sponsored by Novartis. Primary endpoint: Tumor response as assessed by radiologic techniques and/or physical examination based on RECIST. Started Jan 2006; status: completed.
02
Drugs
patupilone
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT00273312.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00273312.